CIK 0001710072 · Large accelerated filer
Edgewise Therapeutics, Inc.
Sign in to watch- Ticker
- EWTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821725586
- Phone
- 720-262-7002
- Business address
- 1715 38TH ST, BOULDER, CO, 80301
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $201,787
- in 1 filing
Net −$201,787. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-01 | Russell Alan J Chief Scientific Officer | Option exercise | +5,209 | 20,072 | ||
| 2025-05-01 | Russell Alan J Chief Scientific Officer | Option exercise · Restricted Stock Units | −5,209 | 0 | ||
| 2025-05-01 | MOORE JOHN R General Counsel | Option exercise | +5,209 | 8,461 | ||
| 2025-05-01 | MOORE JOHN R General Counsel | Option exercise · Restricted Stock Units | −5,209 | 0 | ||
| 2025-05-01 | KOCH KEVIN President and CEO | Option exercise | +10,417 | 24,895 | ||
| 2025-05-01 | KOCH KEVIN President and CEO | Option exercise · Restricted Stock Units | −10,417 | 0 | ||
| 2025-05-01 | Donovan Joanne M. CMO | Option exercise | +10,417 | 26,775 | ||
| 2025-05-01 | Donovan Joanne M. CMO | Option exercise · Restricted Stock Units | −10,417 | 0 | ||
| 2025-05-01 | Derakhshan Behrad Chief Business Officer | Option exercise | +5,209 | 22,046 | ||
| 2025-05-01 | Derakhshan Behrad Chief Business Officer | Option exercise · Restricted Stock Units | −5,209 | 0 | ||
| 2025-05-01 | Carruthers R Michael Chief Financial Officer | Option exercise | +5,209 | 82,328 | ||
| 2025-05-01 | Carruthers R Michael Chief Financial Officer | Option exercise · Restricted Stock Units | −5,209 | 0 | ||
| 2025-04-03 | Thompson Peter A. Director | Purchase | +372,578 | $20.13 | $7.5M | 14,809,075 |
| 2025-04-03 | Thompson Peter A. Director | Purchase | +124,193 | $20.13 | $2.5M | 443,792 |
| 2025-04-03 | ORBIMED ADVISORS LLC Director | Purchase | +372,578 | $20.13 | $7.5M | 14,809,075 |
| 2025-04-03 | ORBIMED ADVISORS LLC Director | Purchase | +124,193 | $20.13 | $2.5M | 443,792 |
| 2025-04-01 | Fox Jonathan C Director | Grant or award | +559 | 11,416 | ||
| 2025-03-07 | Russell Alan J Chief Scientific Officer | Option exercise 10b5-1 | +200 | $0.18 | $36 | 15,063 |
| 2025-03-07 | Russell Alan J Chief Scientific Officer | Sale 10b5-1 | −200 | $30.02 | $6K | 14,863 |
| 2025-03-07 | Russell Alan J Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200 | 1,456,580 |
Page 9 of 26 · 509 trades